BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 8588241)

  • 1. Mechanism of action of mycophenolate mofetil.
    Ransom JT
    Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP.
    Ji Y; Gu J; Makhov AM; Griffith JD; Mitchell BS
    J Biol Chem; 2006 Jan; 281(1):206-12. PubMed ID: 16243838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
    Allison AC; Eugui EM
    Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors.
    Sintchak MD; Nimmesgern E
    Immunopharmacology; 2000 May; 47(2-3):163-84. PubMed ID: 10878288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent].
    Yashima Y; Ohgane T
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):131-7. PubMed ID: 11233304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil and its mechanisms of action.
    Allison AC; Eugui EM
    Immunopharmacology; 2000 May; 47(2-3):85-118. PubMed ID: 10878285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
    Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
    Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of new immunosuppressants.
    Halloran PF
    Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of inosine monophosphate dehydrogenase reduces adipogenesis and diet-induced obesity.
    Su H; Gunter JH; de Vries M; Connor T; Wanyonyi S; Newell FS; Segal D; Molero JC; Reizes O; Prins JB; Hutley LJ; Walder K; Whitehead JP
    Biochem Biophys Res Commun; 2009 Aug; 386(2):351-5. PubMed ID: 19523919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients.
    Goldsmith D; Carrey EA; Edbury S; Smolenski RT; Jagodzinski P; Simmonds HA
    Clin Sci (Lond); 2004 Jul; 107(1):63-8. PubMed ID: 14723604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of IMPDH1 is regulated in response to mycophenolate concentration.
    Bremer S; Vethe NT; Rootwelt H; Bergan S
    Int Immunopharmacol; 2009 Feb; 9(2):173-80. PubMed ID: 19010451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes.
    Jagodzinski P; Lizakowski S; Smolenski RT; Slominska EM; Goldsmith D; Simmonds HA; Rutkowski B
    Clin Sci (Lond); 2004 Jul; 107(1):69-74. PubMed ID: 14723603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
    Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
    Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid.
    Vethe NT; Ali AM; Reine PA; Andersen AM; Bremer S; Line PD; Rootwelt H; Bergan S
    Ther Drug Monit; 2014 Feb; 36(1):108-18. PubMed ID: 24061448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells.
    Dubsky PC; Friedl J; Stift A; Bachleitner-Hofmann T; Jakesz R; Gnant MF; Weigel G
    Clin Chim Acta; 2006 Feb; 364(1-2):139-47. PubMed ID: 16051207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
    Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
    Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide.
    Griesmacher A; Weigel G; Seebacher G; Müller MM
    Clin Chem; 1997 Dec; 43(12):2312-7. PubMed ID: 9439448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolic acid, mycophenolate mofetil, mizoribine, ribavirin, and 7-nitroindole inhibit propagation of Babesia parasites by targeting inosine 5'-monophosphate dehydrogenase.
    Cao S; Aboge GO; Terkawi MA; Zhou M; Kamyingkird K; Moumouni PF; Masatani T; Igarashi I; Nishikawa Y; Suzuki H; Xuan X
    J Parasitol; 2014 Aug; 100(4):522-6. PubMed ID: 24580148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.